Lung Cancer in the Brazilian Health System: Screening, Drug Approvals, Barriers to Care, and Success Stories

Insight Into Genomic Correlates of PD-L1 Expression and the Response to Immune Checkpoint Blockade

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib

Paul G. Kluetz, MD

PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC

Multidisciplinary Tumor Boards: Approaches Across Different Institutions

Shirish Gadgeel, MD

Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy

Karen L. Reckamp, MD, MS

Gideon Blumenthal, MD

David LeDuc

Multidisciplinary Tumor Board: A Single Institution’s Perspective